CIK 0001226616 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | FY2021 | |
|---|---|---|---|---|
| Revenue (USD) | 409657 | 1.0 M | ||
| Net income (USD) | -14.1 M | -13.9 M | ||
| Diluted EPS (USD/shares) | -0.24 | -0.17 | -0.29 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-09-29 | 4 | 4 | 2026-09-25 |
| 2026-09-29 | SCHEDULE 13D/A | SCHEDULE 13D/A | |
| 2026-09-28 | 8-K | 8-K items 1.01 | 2026-09-23 |
| 2026-09-02 | 8-K | 8-K items 1.02 | 2026-08-31 |
| 2026-08-19 | 8-K | 8-K items 5.02 | 2026-08-17 |
| 2026-08-13 | 10-Q | 10-Q | 2026-06-30 |
| 2026-06-25 | 4 | 4 | 2026-06-23 |
| 2026-06-25 | 4 | 4 | 2026-06-23 |
| 2026-06-25 | 4 | 4 | 2026-06-23 |
| 2026-06-24 | 8-K | 8-K items 5.07 | 2026-06-23 |
| 2026-05-14 | 10-Q | 10-Q | 2026-03-31 |
| 2026-04-29 | ARS | ARS | 2025-12-31 |
| 2026-04-29 | DEFA14A | DEFA14A | |
| 2026-04-29 | DEF 14A | DEF 14A | 2026-06-23 |
| 2026-04-20 | PRER14A | PRER14A | |
| 2026-04-17 | PRE 14A | PRE 14A | 2026-06-23 |
| 2026-03-10 | 10-K | 10-K | 2025-12-31 |
| 2026-02-20 | 8-K | 8-K items 2.02,9.01 | 2026-02-20 |
| 2026-01-20 | 4 | 4 | 2026-01-16 |
| 2026-01-20 | 4 | 4 | 2026-01-16 |
| 2025-12-30 | 424B5 | 424B5 | |
| 2025-12-30 | 8-K | 8-K items 1.01,9.01 | 2025-12-29 |
| 2025-12-11 | EFFECT | EFFECT items ,, | |
| 2025-12-09 | CORRESP | CORRESP | |
| 2025-12-05 | S-3 | S-3 |
Forms on file (last 1,000): 8-K 277, 4 243, 10-Q 65, 3 43, DEF 14A 23, 10-K 22, SC 13G/A 21, 424B5 16. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=MNOV (0.002 USD), /gw/filings/filings?ticker=MNOV&form=8-K, /gw/filings/facts?ticker=MNOV&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange